CGEM
NASDAQ · Biotechnology
Cullinan Therapeutics Inc
$14.61
+0.97 (+7.11%)
Financial Highlights (FY 2025)
Revenue
156.49M
Net Income
-25,188,754
Gross Margin
61.0%
Profit Margin
-16.1%
Rev Growth
+6.1%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 61.0% | 61.0% | 61.0% |
| Operating Margin | -16.5% | -14.9% | -14.6% |
| Profit Margin | -16.1% | -18.0% | -15.5% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Gross Profit | 95.45M | 85.57M | 78.83M |
| Operating Income | -25,841,157 | -20,880,510 | -18,861,418 |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Gross Margin | 61.0% | 61.0% | 61.0% |
| Operating Margin | -16.5% | -14.9% | -14.6% |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| Rev Growth | +6.1% | +12.8% | -3.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 34.83M | 35.06M | 41.53M |
| Total Equity | 464.14M | 436.45M | 409.65M |
| D/E Ratio | 0.08 | 0.08 | 0.10 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |